In a new job - September 9, 2020
Oasmia Pharmaceutical appoints new Chief Financial Officer
Oasmia Pharmaceutical has announced the appointment of Fredrik Järrsten as Chief Financial Officer reporting to Francois Martelet, Chief Executive Officer. “We are delighted to have Fredrik joining the Oasmia team as Chief Financial Officer. His vast experience as a leader, developing businesses across the healthcare and life sciences sector, will be invaluable to Oasmia as […]
New Market - February 4, 2020
Oasmia launches its ovarian cancer treatment drug in Sweden, Denmark and Finland
Oasmia Pharmaceutical is launching its product, Apealea 60 mg, an ovarian cancer treatment drug, in Sweden, Denmark and Finland. The first batch of the drug has been shipped to distributors in these countries, states the company. Transition towards becoming a fully integrated pharmaceutical company Apealea is a patented, water-soluble, intravenously injectable formulation of paclitaxel, developed […]
New Market - August 15, 2017
Oasmia receives market approval in Russia
Oasmia Pharmaceutical has received marketing approval of Doxophos in Russia. The company marks this as a key milestone following the recently established relationship with Hetero Group, its new marketing and distribution partner. Doxophos has been approved for use in the treatment of acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic leukemia, Hodgkin’s disease and non-Hodgkin’s lymphoma, […]
